- Home
- CRL vs RYTM Comparison
CRL vs RYTM Comparison
Compare CRL & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRL
- RYTM
- Stock Information
- Founded
- CRL 1947
- RYTM 2008
- Country
- CRL United States
- RYTM United States
- Employees
- CRL N/A
- RYTM N/A
- Industry
- CRL Biotechnology: Commercial Physical & Biological Resarch
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- CRL Health Care
- RYTM Health Care
- Exchange
- CRL Nasdaq
- RYTM Nasdaq
- Market Cap
- CRL 7.3B
- RYTM 6.9B
- IPO Year
- CRL 2000
- RYTM 2017
- Fundamental
- Price
- CRL $163.99
- RYTM $102.12
- Analyst Decision
- CRL Buy
- RYTM Strong Buy
- Analyst Count
- CRL 14
- RYTM 13
- Target Price
- CRL $186.00
- RYTM $101.92
- AVG Volume (30 Days)
- CRL 804.9K
- RYTM 570.8K
- Earning Date
- CRL 11-05-2025
- RYTM 11-04-2025
- Dividend Yield
- CRL N/A
- RYTM N/A
- EPS Growth
- CRL N/A
- RYTM N/A
- EPS
- CRL N/A
- RYTM N/A
- Revenue
- CRL $4,028,615,000.00
- RYTM $156,287,000.00
- Revenue This Year
- CRL N/A
- RYTM $44.69
- Revenue Next Year
- CRL $1.94
- RYTM $63.53
- P/E Ratio
- CRL N/A
- RYTM N/A
- Revenue Growth
- CRL N/A
- RYTM 53.55
- 52 Week Low
- CRL $91.86
- RYTM $45.91
- 52 Week High
- CRL $230.02
- RYTM $106.52
- Technical
- Relative Strength Index (RSI)
- CRL 56.33
- RYTM 60.62
- Support Level
- CRL $157.20
- RYTM $101.45
- Resistance Level
- CRL $165.22
- RYTM $106.52
- Average True Range (ATR)
- CRL 3.97
- RYTM 3.12
- MACD
- CRL 0.38
- RYTM -0.43
- Stochastic Oscillator
- CRL 78.43
- RYTM 65.84
About CRL Charles River Laboratories International Inc.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.